Navigation Links
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
Date:9/14/2010

l StudiesThe two fidaxomicin Phase 3 clinical studies were multi-center, randomized, double-blind trials, which enrolled a total of 1,164 adult subjects.  Subjects with confirmed CDI received either fidaxomicin (200 mg q12h) or Vancocin® (125 mg q6h), the only FDA approved product for the treatment of CDI. These studies were designed to evaluate safety and compare the response to treatment in subjects during and after a 10-day course of therapy. The primary endpoint was non-inferiority compared to Vancocin in clinical cure (defined as patients requiring no further CDI therapy two days after completion of study medication, as determined by the investigator).  If cured, subjects were monitored for a subsequent four-week period to evaluate recurrence, which was a secondary endpoint.  Global cure, also a secondary endpoint, was defined as patients who were cured and did not have a recurrence during this subsequent four-week period. In both of these studies, fidaxomicin achieved its primary endpoint of non-inferiority compared to Vancocin.  Fidaxomicin was also statistically superior to Vancocin in global cure rate and in reducing recurrences of CDI.

About Clostridium difficile InfectionCDI has become a significant medical problem in hospitals, long-term care facilities, and in the community.  It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produces toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, and thus allowing C. difficile bacteria to flourish.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially res
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
9. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Stemedica Announces Completion of Clinical Stem Cell Master Bank
11. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Iowa (PRWEB) September 02, 2014 Press ... of ways to take advantage of the people and ... the schedule below are available throughout the day. Additionally, ... requests with POET and DSM representatives as well as ... interview requests is appreciated. , Please remember to ...
(Date:9/2/2014)... 02, 2014 Myriant Corporation, a ... of a distribution agreement with Azelis Group, a ... Myriant’s bio-succinic acid in the Nordics, Benelux, France, ... customers in the industrial and base chemicals markets. ... offers a far-reaching chemical portfolio with extensive distribution ...
(Date:9/2/2014)... Inc. (Nasdaq: ONTY ) announced today that ... present at the Rodman & Renshaw 16 th Annual ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... will be accessible by visiting the Oncothyreon website www.oncothyreon.com ... About Oncothyreon Oncothyreon is a biotechnology company ...
(Date:9/2/2014)...  Spherix Incorporated (SPEX) -- an intellectual property development company committed ... announced that the United States Patent & Trademark Office ... month of August that are part of a standard ... patents are: , U.S.RE45,065 issued August ... and , U.S.RE45,095 issued August 26, 2014.  ...
Breaking Biology Technology:Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2
... For Women in Science program is welcoming the 15 International Fellows ... , On Wednesday, March 28, from 4 pm to ... the Pasteur Institute in Paris. Following these presentations, a cocktail ... be met individually , , On ...
... physics of massive particles has intrigued physicists for more than ... exhibit wave-like behaviour in conflict with our everyday ideas ... of scientists now succeeded in shooting a movie which shows ... molecules which is so large (up to 0.1 mm) that ...
... March 22, 2012 /PRNewswire-iReach/ -- FirstMark, the ... announce that the company will be exhibiting at the ... College of Cardiology (ACC) in Chicago, March 24-27, Booth ... PREvent is the first and only multiple biomarker blood ...
Cached Biology Technology:The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 2The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 3The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 4Single molecules in a quantum movie 2FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo 2
(Date:9/2/2014)... milk is considered the most ideal source of ... a critical role in the evolution and civilizations ... milk contains a large number of bacterial species, ... comes as no surprise to scientists and physicians. ... considered to be the result of co-evolutionary and ...
(Date:9/2/2014)... between our immune systems and cholera bacteria, humans may ... phages. In a new study, researchers from Tufts University, ... Health Laboratory, and elsewhere, report that phages can force ... to survive. Importantly, the study published in ... phage predation occurs during human infection. , First author ...
(Date:9/2/2014)... the price of your integrity? Tell the truth; everyone has ... at some point, we,ll lie if the benefit is great ... in which we make that decision. , The result ... . , "We prefer to be honest, even if ... and a postdoctoral associate at the Virginia Tech Carilion ...
Breaking Biology News(10 mins):Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4
... Medicine researchers played a key role in the largest ... 11 new regions of the genome that contribute to ... therapeutic targets to investigate. Published October 27 in ... of the genetic factors contributing to Alzheimer,s and expands ...
... A group of students and faculty at Grand Valley State ... new methods to further a growing medical field that aims ... group of four Grand Valley students and graduates, and Anthony ... the World Molecular Imaging Congress, one of the largest meetings ...
... Ore. -- (Oct. 25, 2013) -- Twenty grams of essential amino ... weeks after knee-replacement surgeries helped 16 patients, mean age 69, recover ... ingesting a placebo. The approach -- detailed in a paper ... the Journal of Clinical Investigation -- could spell relief ...
Cached Biology News:International collaboration finds 11 new Alzheimer's genes to target for drug discovery 2GVSU students contribute to growing medical field 2Oregon researchers say supplement cuts muscle loss in knee replacements 2Oregon researchers say supplement cuts muscle loss in knee replacements 3Oregon researchers say supplement cuts muscle loss in knee replacements 4
...
Human/Mouse/Rat p38 alpha Affinity Purified PAb...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Biology Products: